Search
GU Cancer
S1931
Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
A151804
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
A031702 (Cohort B (adenocarcinoma of the bladder), E (penile cancer), F (sarcomatoid renal cell carcinoma), G (miscellaneous GU tract histologic variants), I (renal medullary carcinoma) and Cohort K (Renal Collecting Duct Carcinoma) are Temporarily Closed to Accrual)
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
S1802
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
A031701
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
AGCT 1531 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
